Efficacy And Safety Analysis Of Liraglutide And Intermittent Fasting On Newly Diagnosed Overweight/obese Patients With Type2 Diabetes Mellitus

Objective:To investigate the efficacy and safety of Intermittent fasting(IF)program and Liraglutide(Lir)for patients with newly diagnosed Type2 diabetes mellitus(T2DM).Methods:A total of 150 newly diagnosed overweight/obese patients with T2 DM were randomly divided into two groups according to different treatment regimen,which were called IF group and Lir group.Each group has 75 subjects.The Lir group was treated with metformin hydrochloride combined with Lir,and the IF group was treated with metformin hydrochloride combined with IF regimen.Follow-up for 12 weeks,analysis of body weight,body mass index(BMI),waist-hip ratio(WHR),fasting plasma glucose(FPG),glycated hemoglobin(Hb A1c),fasting serum Insulin(FINS),serum C-peptide,Homeostasis model assessment-insulin resistance(HOMA-IR),total cholesterol(TC),triglyceride(TG),low-density lipoprotein(LDL),high density lipoprotein(HDL),systolic blood pressure(SBP),diastolic blood pressure(DBP)changes compared with baseline,and monitor nausea,occurrence of adverse reactions such as vomiting,diarrhea,and hypoglycemia.SPSS23.0 was the statistical analysis software used in this study,and P < 0.05 meant the difference was statistically significant.Results:1.Comparison of baseline dataThere were no significant differences in Age,height,weight,Sex,blood pressure,lipid metabolism indexes,FINS,serum C-peptide,HO MA-IR and other baseline data between the two groups(P > 0.05).2.Changes of FPG,Hb A1 c,TC,TG,LDL and HDLAfter treatment,FPG,Hb A1 c,TC,TG and LDL were decreased and HDL was increased in the two groups compared with baseline,and the differences were statistically significant(P < 0.05).There was no significant difference between the two groups(P > 0.05).3.Changes of body weight,BMI,WHR,FINS,serum C-peptide and HOMA-IRAfter treatment,body weight,BMI,WHR,FINS,serum C-peptide and HOMA-IR were decreased in the two groups compared with baseline,and the differences were statistically significant(P < 0.05).The difference between the two groups was statistically significant(P < 0.05).4.Changes of SBP and DBPAfter 12 weeks of treatment,SBP and DBP decreased in the two groups compared with baseline and the difference was statistically significant(P <0.05).There was significant difference in SBP between the two groups(P <0.05).5.Security assessmentDizziness occurred in 4 cases(5.30%)and hypoglycemia in 3 cases(4.00%)in the IF group.In Lir group,nausea occurred in 3 cases(4.00%),diarrhea in 2 cases(2.70%)and hypoglycemia in 1 case(1.30%).There was no significant difference in adverse reactions between the two groups(P >0.05).Conclusions:1.Both IF regimen and Lir can reduce body weight,BMI,WHR,FINS,HOMA-IR,SBP,DBP and related indexes of glycemic and lipid metabolism in newly diagnosed overweight/obese T2 DM patients,and there is no significant difference between the two regimen in glycemic and lipid lowering effects.2.There is no significant difference between IF regimen and Lir in the incidence of hypoglycemia,nausea,diarrhea and other adverse reactions,and the safety is satisfactory.